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Abstract
Background: To evaluate the impact of structural changes of the retinal nerve fiber layer (RNFL), and visual field
loss, on functional impairment assessed by patient-reported visual functioning in glaucoma.
Methods: Patients with glaucomatous optic nerve damage were enrolled in this cross-sectional study. Peripapillary
RNFL thickness was obtained with spectral-domain optical coherence tomography (SD-OCT). Function was
assessed by patient-reported visual functioning using the Rasch-calibrated Glaucoma Activity Limitation 9 (GAL-9)
questionnaire and standard automated perimetry. The impact of peripapillary RNFL loss on functional impairment
was analyzed with correlation and linear regression analyses.
Results: A total of 176 eyes from 88 glaucoma patients were included. The SD-OCT assessed temporal-superior
and temporal-inferior RNFL sector of the worse eye revealed significant correlation with the GAL-9 scores (r=-0.298,
p=0.011 and r=-0.251, p=0.033, respectively). In mutivariate regression analysis, the best predictors for patient-
reported visual functioning were visual acuity of the better eye and mean defect of the worse eye (R2=0.334), while
structural parameters could not enhance the prediction of GAL-9 scores.
Conclusions: Self-reported visual functioning of patients with glaucoma is better predicted by visual performance
data than structural parameters. However, some structural changes of the worse eye are significantly correlated with
patient-reported visual functioning.
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Introduction
Glaucoma is one of the leading causes of blindness with
more than 70 million people affected worldwide[1]. However,
blindness from glaucoma can be prevented by early diagnosis
and treatment. Structural changes in glaucoma can be
detected in the peripapillary retinal nerve fiber layer (RNFL), in
the retinal ganglion cell layer complex and in the optic nerve
head. Functional impairment of patients with glaucoma
includes defects of the visual field with consecutively
decreased visual functioning. Numerous studies have shown a
correspondence between structure and function across the
spectrum with all stages of glaucoma [2-4].
Precise measurements of the RNFL thickness are feasible
with optical coherence tomography (OCT)[5], particularly with
high resolution spectral domain (SD) OCT imaging. A
relationship between RNFL thickness and functional
parameters has been demonstrated[3]. [4] A number of studies
have investigated the relationship between global perimetric
indices (e.g. mean deviation, MD) and patient-reported visual
functioning [6,7], but the relationship between structural
changes in patients with glaucoma and patient-reported visual
functioning is less clear. This relationship seems logical given
the fact that structural changes affect vision, which in turn
affects functioning; therefore, both measures, those of structure
and vision, should be correlated with visual functioning. The
nature of these correlations will depend upon the extent to
which the measures of structure and the measures of vision
capture deficits of importance for visual functioning. Glaucoma
patients often report a diminished quality of life and visual
functioning[8]. [9] In early glaucoma, quality of life is challenged
by the need for continuous therapy, regular consultations and
to some extent stressful repeated examinations (e.g. perimetry)
[10,11]. In advanced glaucoma, patients´ quality of life is
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reduced due to visual field defects and the loss of functioning
these cause[12]. Assessing the impact of the disease for the
glaucoma patient is vital for optimizing individual advice and
therapy. A number of patient-reported outcomes (PROs) exist
for measuring quality of life or visual functioning in
glaucoma[13-18]. The Glaucoma Activity Limitation 9 (GAL-9)
is a well evaluated glaucoma-specific questionnaire designed
to measure visual functioning[19]. [20,21] Importantly, that the
GAL-9 is the only glaucoma-specific PRO to be successfully
revalidated using Rasch analysis[19]. This is important for PRO
scoring with the estimation of interval-scaled measures from
ordinal data facilitating parametric statistical analyses such as
relationship testing with linear regression[22].
This study was performed to evaluate the structure/function/
patient-reported visual functioning relationships in patients with
glaucoma. Structural peripapillary RNFL thickness was
obtained using the SD-OCT, function was assessed with
standard automated perimetry and visual acuity (VA), and
patient-reported visual functioning was measured with the
GAL-9. A secondary aim was to look for differences in the
predictive value of structural and functional parameters
depending on weather the better or the worse eye is regarded.
Patients and Methods
This was a cross-sectional investigation conducted in a
German university-affiliated glaucoma center: the glaucoma
unit of the Department of Ophthalmology, Ludwig-Maximilians-
University, Munich, Germany. Potential study participants,
patients with glaucoma attending for a regular review, were
approached on a consecutive basis. All study participants
underwent a full ophthalmic examination, including objective
and subjective refraction, slit-lamp biomicroscopy, intraocular
pressure (IOP) measurement with Goldmann applanation
tonometry, gonioscopy, dilated fundus examination by indirect
ophthalmoscopy and central corneal thickness (CCT)
measurement. Inclusion criteria were age >18 years and a
spherical refraction between -7.0 and +5.0 diopters. Patients
with all stages of primary and secondary glaucomatous optic
nerve damage undergoing all types of treatment or surgery
were included. However, cases with secondary glaucoma
associated with systemic disorders were excluded to minimize
a potential confounding influence of comorbidity. Patients with
a visual acuity of less than 20/50 in the better eye were
excluded, as the items of the GAL-9 require at least minimal
visual function for utilizable results. Further exclusion criteria
included diabetes or history of other ocular or neurologic
diseases. Approximately every tenth consecutive patient could
not be enrolled due to unreliable standard automated perimetry
or not meeting the 15 dB threshold for image quality in SD-
OCT.
Glaucomatous eyes were defined as those with reliable
abnormal standard automated perimetry (at least 3 adjacent
points had a >= 5 dB or at least 1 point had a >= 10 dB loss in
compared numerical map) and optic nerve damage (rim
thinning, notching, excavation, or retinal nerve fiber layer
defect). Ethical approval of the study was obtained from the
Institutional Review Board of the University Eye Hospital
Munich in Germany and all the patients who agreed to
participate signed a consent form. The study adheres to the
tenets of the Declaration of Helsinki.
GAL-9 testing
There have been two recent reviews of PRO measures for
glaucoma patients[23,24] that identified five superior quality
disease-specific questionnaires. We considered each of these
PROs and elected to use the Glaucoma Activity Limitation 9
(GAL-9), derived from the Glaucoma Quality of Life
questionnaire (GQL-15) originally developed by Nelson et al.
[20] This was because the GAL-9 focusses purely on visual
functioning and contains a large number of; this appeared to
offer the best prospects for correlating with structure metrics. In
recent studies, the GAL-9 was analyzed in the German
translation showing excellent measurement precision[19].
However, the items showed suboptimal targeting to the ability
of the persons because, on average, they were too easy. Poor
targeting is an inevitable problem for PRO questionnaires in
glaucoma[25], including the widely used visual functioning
questionnaire (VFQ-25)[26], because the overwhelming
majority of patients with glaucoma have normal vision in at
least one eye and excellent patient-reported visual functioning.
Accepting this premise, the GAL-9 is the best available
instrument for use in this study. The psychometric evaluation of
the GAL-9 is explained in detail elsewhere[19]. All the items in
the GAL-9 are scored on a 5-category difficulty scale ranging
from 1 to 5 with labels of “no difficulty”, “a little bit of difficulty”,
“some difficulty”, “quite a lot of difficulty” and “severe difficulty.”
An additional category “Do not perform for non-visual reasons”
was scored as missing data for the final analysis. The GAL-9
responses were transformed into person estimates using
Rasch analysis. Rasch analysis is a probabilistic mathematical
model which estimates item difficulty, person ability and the
threshold for each response category on a single continuum
logit scale. For this analysis, the person with higher ability
(people less affected by the disease) and items of greater
difficulty are located on the negative side of the logit scale and
vice versa. In a prior analysis, it was shown that the GAL-9
enables unidimensional measurement of visual functioning with
excellent psychometric attributes[19]. The use of Rasch
analysis removes noise from the measurement and increases
the likelihood of detecting significant relationships between
variables[27]. In this study, the German version of the GAL-9
was self-administered by the patients in the clinic before the
clinical examination or visual field testing began.
SD-OCT testing
SD-OCT-based assessment of the RNFL provides a
technological advance in the diagnosis of glaucoma[28]. The
different SD-OCT instruments have similar abilities to detect
glaucomatous RNFL damage[29]. For SD-OCT assessment of
the RNFL, a Spectralis OCT was used (Spectralis HRA&OCT;
software version 5.2.0.3, Heidelberg Engineering, Germany).
This device uses a dual-beam SD-OCT and a confocal laser
scanning ophthalmoscope that works by emitting a
superluminescent diode light with a center wavelength of 870
nm and an infrared scan to simultaneously provide images of
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ocular microstructures. For RNFL measurements 16
consecutive circular B-scans are automatically averaged and
compared with a normative database. The signal of the
examination had to be at least 15 dB to be included in the
study; a commonly used cut off level for obtained scans[29,30].
The eye with the lower global RNFL thickness values for a
given patient was considered to be the worse eye with respect
to structural damage on SD-OCT testing.
Perimetry
Standard automated perimetry is currently the gold standard
for visual field testing. Visual field was assessed using the
Humphrey Field Analyzer (HFA, Humphrey Instruments Inc.,
CA, USA) and the SITA 30-2 standard algorithm; whereby the
parameters mean deviation (MD) and the pattern standard
deviation (PSD) were recorded. A reliable visual field test was
defined as having a <25% rate of fixation losses, and <20%
false positive and false negative values. The MD was used to
determine, which eye of each patient was the better or worse
eye; the eye with the lower MD was considered to be the worse
eye (more glaucomatous damage). Glaucoma staging was
determined following a simplified Hodapp-Anderson-Parrish
modification [31,32] as early (=>-6dB), moderate (>-6dB and




We performed Rasch analysis on the German GAL-9 using
Winsteps software (version 3.68), Chicago, Illinois, USA. The
Andrich rating scale model was used and four rating scales
were applied (see [19] [26] for more details).
Visual acuity mean values were calculated using log
minimum angle of resolution (logMAR) values. Descriptive
statistical analyses were performed to characterize the
patients’ clinical, functional and structural data. Difference
testing between eyes was done using the Student t-test. For
correlation analysis, the Pearson correlation coefficient was
calculated for normally distributed values (according to the
Kolmogorov-Smirnov test), otherwise the Spearman’s rank
coefficient was used. Relationships were also tested with
multiple linear regression; t-based 95% confidence intervals
(CIs) for the regression coefficients were used. All statistical
analyses were performed with the SPSS statistical software
(Version 17.0, SPSS Science, Chicago, IL).
Results
A total of 88 patients were included (176 eyes); fifty-one
(58.0%) patients were female. Perimetry, GAL-9 testing and
SD-OCT of the peripapillary RNFL were obtained from all
patients. The best-corrected VA of the MD-guided better eye
was 20/28 (logMAR 0.14) and of the worse eye 20/33 (logMAR
0.21, Table 1). Central corneal thickness and IOP were not
significantly different in MD-guided better and worse eyes on
Student-t testing. On the basis of MD of the better eyes, 72.7%,
15.9% and 11.4% of the study population were classified as
having early, moderate and advanced form of glaucoma
following the modified grading system of Hodapp-Anderson-
Parrish. When considering worse eyes, 50%, 26.1% and 23.9%
had early, moderate and advanced glaucoma.
Mean RNFL thickness was lower in each sector in the MD-
guided worse eyes (Table 1). Rasch analysis revealed GAL-9
values from -6.13 (best glaucoma-specific visual function) to
2.67 (worst glaucoma-specific visual function).
Correlation analyses
RNFL thickness for all sectors and GAL-9 person estimates
were normally distributed on Kolmogorov-Smirnov testing, VA
and perimetrical data were not normally distributed. The most
relevant correlations are displayed in Table 2. There were no
significant correlations between the RNFL thickness of the
Table 1. Demographic, biometric and clinical characteristics including the spectral-domain optical coherence tomography
(SD-OCT) assessed retinal nerve fibre layer (RNFL) thickness (mean values +/- 1 SD).
Age (years) 63.2 +/- 13.4
GAL-9 person estimate -2.45 +/- 2.01
 MD guided b/e MD guided w/e
VA, logMAR 0.14 +/- 0.23 0.21 +/- 0.28
IOP (mmHg) 13.7 +/- 3.23 13.7 +/- 4.19
CCT (µm) 548 +/- 35 548 +/- 36
Mean defect (dB) -4.0 +/- 5.1 -7.1 +/- 5.9
Pattern standard deviation 4.2 +/- 3.0 6.1 +/- 3.9
SD-OCT sector (µm)   
 temporal 64 +/- 14 55 +/- 19
 temporal-superior 95 +/- 30 85 +/- 28
 nasal-superior 72 +/- 18 70 +/- 22
 nasal 60 +/- 20 60 +/- 16
 nasal-inferior 86 +/- 22 77 +/- 21
 temporal-inferior 101 +/- 38 85 +/- 38
doi: 10.1371/journal.pone.0080757.t001
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better eyes and GAL-9 assessed functional impairment.
However, there were moderate significant correlations between
the temporal-superior and temporal-inferior sector of the worse
eye and GAL-9 scores (r=-0.298, p=0.011 and r=-0.251,
p=0.033, respectively). The correlations are negative, because
patients with better functioning are located on the negative side
of the logit scale.
The MD values of better and worse eyes were highly
correlated with the RNFL thickness measurements, and
correlations between RNFL thickness and MD were higher for
the worse eye. The highest correlations of all RNFL sectors
were observed for the temporal-superior and temporal-inferior
sector of the worse eye with the MD of the worse eye (r=0.527,
p<0.001 and r=0.671, p<0.001, respectively). The global RNFL
of the worse eye was highly correlated with the MD of the
worse eye (r=0.668, p<0.001).
Regarding functional parameters and patient-reported visual
functioning, there was a trend to a higher correlation of GAL-9
scores with the MD of the better eye than GAL-9 score with the
MD of the worse eye (r=-0.479, p<0.001 and r=-0.373,
p<0.001).
Linear Regression Models
Linear regression analyses were performed to analyze the
impact of RNFL loss on functional parameters and patient-
reported visual functioning. SD-OCT-assessed RNFL thickness
of each sector of the MD-guided better or worse eye entered
linear regression to predict GAL-9 person estimates (Table 3).
A multivariate linear regression analysis was performed to
predict GAL-9 person estimates entering significant structural
and functional parameters. The best model to predict GAL-9
person estimates includes the VA of the worse eye and the MD
of the better explaining 33.4% of the variance in patient-
reported visual functioning (Table 4). This represents an
improvement over VA w/e 19.6% and MD b/e 27.9% alone.
Adding SD-OCT assessed RNFL metrics did not enhance the
predictive power in multivariate linear regression and are
therefore not presented.
Discussion
To the best of the authors´ knowledge, this is the first study
that compares glaucomatous RNFL thickness and patient-
reported visual functioning. It could be hypothesized that
structural change should lead to visual change, which in turn
should impact person-reported measurements. However, a
Table 2. Correlation analysis between important functional parameters and IOP, CCT and RNFL sectors (T: temporal, TS:
temporal superior, NS: nasal superior, N: nasal, NI: nasal inferior, TI: temporal inferior, G: global) for better eye (b/e) and
worse eye (w/e), respectively.
 GAL-9 VA b/e VA w/e MD b/e MD w/e
 correl. p correl. p correl. p correl. p correl. p
Age 0.102 0.398 0.287 0.021 0.356 0.004 -0.148 0.245 -0.222 0.088
VA b/e 0.303 0.014     -0.330 0.010 -0.070 0.594
VA w/e 0.416 0.000     -0.335 0.010 -0.316 0.018
MD b/e -0.479 0.000         
MD w/e -0.373 0.000         
IOP b/e -0.019 0.816 -0.144 0.087 -0.092 0.277 0.107 0.417 -0.004 0.976
IOP w/e -0.093 0.268 0.054 0.524 -0.162 0.053 -0.024 0.857 -0.171 0.203
CCT b/e 0.136 0.134 0.072 0.432 -0.003 0.973 -0.063 0.522 0.149 0.153
CCT w/e 0.048 0.605 0.093 0.317 0.038 0.680 -0.071 0.473 0.141 0.175
RNFL T b/e 0.113 0.339 -0.041 0.742 0.034 0.786 0.265 0.033 0.154 0.231
RNFL T w/e 0.016 0.895 0.073 0.558 -0.328 0.007 0.314 0.012 0.436 0.000
RNFL TS b/e -0.081 0.498 -0.129 0.298 0.037 0.764 0.456 0.000 0.311 0.013
RNFL TS w/e -0.298 0.011 -0.247 0.045 -0.247 0.046 0.433 0.000 0.527 0.000
RNFL NS b/e -0.021 0.861 -0.001 0.990 -0.058 0.642 0.287 0.020 0.158 0.220
RNFL NS w/e 0.030 0.804 -0.073 0.562 0.032 0.798 0.146 0.250 0.263 0.041
RNFL N b/e -0.106 0.370 0.044 0.721 -0.173 0.162 0.303 0.014 0.193 0.133
RNFL N w/e 0.118 0.325 0.012 0.922 -0.108 0.388 0.215 0.088 0.372 0.003
RNFL NI b/e -0.197 0.094 -0.104 0.403 -0.178 0.149 0.520 0.000 0.331 0.009
RNFL NI w/e -0.059 0.620 0.049 0.697 -0.317 0.009 0.256 0.046 0.399 0.001
RNFL TI b/e -0.221 0.061 -0.232 0.059 -0.219 0.075 0.639 0.000 0.562 0.000
RNFL TI w/e -0.251 0.033 0.084 0.502 -0.320 0.009 0.394 0.001 0.671 0.000
RNFL G b/e -0.174 -0.14 -0.141 0.254 -0.112 0.336 0.673 0.000 0.514 0.000
RNFL G w/e -0.075 0.530 -0.010 0.937 -0.318 0.009 0.435 0.000 0.668 0.000
Cursive numbers are Pearson´s correlation coefficients, otherwise Spearman rank coefficients are displayed. Significant coefficients (p<0.05) are bold.
doi: 10.1371/journal.pone.0080757.t002
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major finding of our study is that the RNFL is not well
correlated or highly predictive for the GAL-9. There seems to
be a degree of separation between structural and patient-
reported changes. The functional parameters visual acuity and
MD predict GAL-9 scores much better than the SD-OCT
assessed structural parameter RNFL.
In studies that explore structure-function relationships in
ophthalmology and in glaucoma in particular, it has to be
considered that most patients have a worse and a better
eye[33]. The overall best model to predict GAL-9 scores
include VA of the worse eye and perimetric MD of the better
eye (R2=0.334). The finding that the VA of the worse eye is a
better predictor for functional impairment is noteworthy, as
numerous previous publications suggested that patient-
reported visual functioning is at least partially driven by the eye
with the better visual acuity [34,35]; particularly in eyes with
cataract. Therefore, this is an intriguing finding, although this
has been found in glaucoma before. Our findings are
consistent with a recent study by Gothwal et al., who report a
far better correlation of the patient-reported visual functioning
using the Glaucoma Activity Limitation 10 score with the VA of
the worse eye (r=0.49) than with the VA of the better eye
(r=0.35) [36]. Gothwal et al hypothesized that this may be due
to the limited variance in the good eye reducing the power to
detect a relationship. However, in our data this can only be a
minor role with the better eye and the worse eye having similar
variance (SD b/e ±0.23, w/e ±0.28). The finding of a stronger
influence of the MD of the better eye on patient-reported visual
functioning has also been reported previously [36,37]. Other
studies in glaucoma have reported that the worse eye is the
one that correlates better with function, when function was
directly measured and set in comparison to clinical values,
including visual fields[38-40]. This suggests that vision loss in
one eye in glaucoma has an effect on the patient that cannot
be overcome by the better eye. It has been observed in other
eye diseases that the worse eye with stable function of the
fellow eye has significant impact on patients´ reported outcome
[34,41]. Bressler et al. reported a clinically significant increase
of patients´ quality of life when the worse eye with wet age-
related macular degeneration was treated, although the
binocular visual acuity did not increase[42].
As expected, structural parameters and perimetric
performance were highly correlated, with a correlation
coefficient of 0.668 between the global RNFL of the worse eye
was and the MD of the worse eye. This is because the
measured structural changes directly related to the loss of
visual field. This compares favorably with previous studies[3].
[4] However, this global impairment of the RNFL does not
Table 3. Univariate linear regression.
  Adj. R2 Coefficient P  Adj. R2 Coefficient p
Age  0.032 0.179 0.023     
VA b/e 0.086 0.294 0.000 w/e 0.196 0.443 0.000
IOP b/e 0.001 -0.019 0.816 w/e 0.009 -0.093 0.268
CCT b/e 0.019 0.136 0.134 w/e 0.002 0.048 0.605
MD b/e 0.279 -0.528 0.000 w/e 0.196 -0.443 0.000
PSD b/e 0.144 0.379 0.000 w/e 0.021 0.143 0.112
CDR b/e 0.047 -0.217 0.095 w/e 0.020 -0.142 0.280
RNFL T b/e 0.013 0.113 0.339 w/e 0.001 0.016 0.895
RNFL TS b/e 0.007 -0.081 0.498 w/e 0.089 -0.298 0.011
RNFL NS b/e 0.001 -0.021 0.861 w/e 0.001 0.030 0.804
RNFL N b/e 0.011 -0.106 0.370 w/e 0.014 0.118 0.325
RNFL NI b/e 0.039 -0.197 0.094 w/e 0.004 -0.059 0.620
RNFL TI b/e 0.049 -0.221 0.061 w/e 0.063 -0.251 0.033
RNFL G b/e 0.030 -0.174 0.141 w/e 0.006 -0.075 0.530
Dependent variable GAL-9. Visual acuity (VA) and mean defect (MD) were significant predictors for GAL-9 scores with the MD of the better eye revealing best modelling
(R2=0.279). The only significant predictor of structural parameters was the retinal nerve fibre layer (RNFL) of the temporal superior (TS) sector of the worse eye. IOP:
intraocular pressure, CCT: central corneal thickness, PSD: pattern standard deviation, CDR: cup-to-disc ratio.
doi: 10.1371/journal.pone.0080757.t003
Table 4. Best model in multiple regression analysis to predict GAL-9 scores.
 Adjusted R2 Coefficient p
GAL-9 0.334   
VA of w/e  0.309 0.014
MD of b/e  -0.373 0.003
Adding any sector of the RNFL or age did not enhance the predictive power.
doi: 10.1371/journal.pone.0080757.t004
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directly result in a global reduction in patient-reported visual
functioning. This is likely due to the role of the fellow eye in
driving patient-reported visual functioning, the importance of
RNFL loss for patient-reported visual functioning and patient
adaptation to these losses. Although correlations of structural
parameters with GAL-9 scores were rather low, structural
characteristics displayed by RNFL thickness of the eye with the
worse glaucomatous damage is better correlated with GAL-9
scores than the better eye. It can be suggested that losses in
the worse eye are not fully compensated by the better eye
resulting in functional losses for the person. The significant
correlation with VA (r=-0.320, p=0.009) in the worse eye for the
temporal-inferior peripapillary sector could be explained by the
fact, that this sector receives the majority of the nerve fibers
from the papillo-macular bundle given the off-center position of
the optic nerve head; these fibers carry visual acuity signal.
One previous study has shown that inferio-temporal field loss is
the most predictive of self-reported reading and other visual
functioning[43]. Another explanation for why worse eyes´
structural changes may have driven GAL-9 outcomes more
than the better eye could be a distribution of visual field
damage including many subjects with unilateral visual field
damage and near-normal better eye function, but this was not
the case in our sample. By selecting patients with rather good
visual acuity some bias could have been added to the results.
For patients with good binocular visual acuity, the worse eye
may play a significant role in their performance, whereas for
patients with poor binocular visual acuity (e.g. 20/100 to
20/200), the better eye may be more important. In this study,
there is more variance in the worse eye data which improves
the probability of a strong correlation. However, most patients
with a diagnosis of glaucoma have good central visual acuity,
and therefore, the results appear to be representative of a
randomly selected glaucoma population.
A strength of this study is the use of Rasch-scaled person
estimates of the GAL-9. The GAL-9 was shown to have
excellent psychometric characteristics except for targeting of
item difficulty to person ability[19]. Poor targeting is an
inevitable attribute as most of the glaucoma patients have little
difficulty in performing everyday tasks[44,45]. Furthermore, the
GAL-9 does not reflect overall quality of life as important
aspects like anxiety or depression are not adequately
addressed [46]. Better questionnaires in the future might
enable measurement beyond visual functioning to include
overall quality of life, which might fit better in models including
structural changes. Item banking approaches for glaucoma
quality of life measurement are under development and these
may provide better options for research in this field[47,48]. It
must be considered that we did not add a comorbidity index,
which could be a potential confounder. Another possible
confounder could be that trying to find early glaucomatous
changes with multiple diagnostic tools could make the patients
worry unnecessarily and affect their quality of life. However, the
GAL-9 focusses on activity limitation rather than worry,
therefore this possible confounder is minimized. One should
also keep in mind that quality of life and activity limitation is
partially dependent on patients´ age. We did not adjust our
data for age as there is not sufficient data at the moment to
perform this standardization.
The ultimate gain of glaucoma therapy is to prevent loss of
patients´ quality of life. High quality measurement of structural,
visual and patient-reported outcomes and an understanding of
their inter-relationships is critical to achieving this goal. It would
be of interest to investigate longitudinally, whether localized
RNFL thinning or other structural change in glaucoma can
predict future deficits in patient-reported visual functioning.
New measurements of structural changes, e.g. the optic nerve
head using the minimum rim width by SD-OCT [49], might
reveal higher correlations with visual functioning and might
support the theory that the worse eye has a higher impact in
glaucoma than the better eye.
Conclusions
Structural measurements of the peripapillary RNFL thickness
by SD-OCT are weak predictive factors of patient-reported
visual functioning as assessed by the GAL-9. The best
predictors of patient-reported visual functioning are the visual
acuity of the worse eye and the MD of the better eye.
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